MENU
+Compare
NONOF
Stock ticker: OTC
AS OF
Aug 15 closing price
Price
$51.20
Change
+$0.94 (+1.87%)
Capitalization
226.29B

NONOF stock forecast, quote, news & analysis

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world... Show more

NONOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for NONOF with price predictions
Aug 15, 2025

NONOF's RSI Indicator ascends from oversold territory

The RSI Oscillator for NONOF moved out of oversold territory on August 08, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 10 similar instances when the indicator left oversold territory. In of the 10 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 14, 2025. You may want to consider a long position or call options on NONOF as a result. In of 113 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NONOF just turned positive on August 14, 2025. Looking at past instances where NONOF's MACD turned positive, the stock continued to rise in of 56 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NONOF advanced for three days, in of 260 cases, the price rose further within the following month. The odds of a continued upward trend are .

NONOF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

NONOF moved below its 50-day moving average on July 25, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NONOF declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NONOF entered a downward trend on July 28, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.628) is normal, around the industry mean (9.410). P/E Ratio (13.076) is within average values for comparable stocks, (23.553). Projected Growth (PEG Ratio) (1.502) is also within normal values, averaging (1.848). Dividend Yield (0.034) settles around the average of (0.027) among similar stocks. P/S Ratio (4.658) is also within normal values, averaging (3.361).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NONOF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. NONOF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Dividends

NONOF paid dividends on August 18, 2021

Novo-Nordisk A/S NONOF Stock Dividends
А dividend of $7.00 per share was paid with a record date of August 18, 2021, and an ex-dividend date of August 16, 2021. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 87.46B. The market cap for tickers in the group ranges from 72.83K to 628.62B. LLY holds the highest valuation in this group at 628.62B. The lowest valued company is CRXTQ at 72.83K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 2%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 13%. SCLX experienced the highest price growth at 15%, while CHGCF experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -12%. For the same stocks of the Industry, the average monthly volume growth was -11% and the average quarterly volume growth was -4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 31
P/E Growth Rating: 69
Price Growth Rating: 52
SMR Rating: 61
Profit Risk Rating: 79
Seasonality Score: -19 (-100 ... +100)
View a ticker or compare two or three
NONOF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
N/A
Address
Novo Alle 1
Phone
+45 44448888
Employees
64319
Web
https://www.novonordisk.com